Nanda Horeweg

Has grant

Assistant Professor

Leiden University Medical Center

Netherlands

Research Interests

Explore related searches

Professors in Netherlands Professors in Medical Imaging Medical Imaging professors in Netherlands

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Nanda Horeweg is an Assistant Professor at Leiden University Medical Center in the Netherlands. His research primarily focuses on endometrial cancer, exploring areas such as clinical and molecular characteristics, prognostic classifications, and innovative treatment methodologies. Recent publications highlight his work on biomarker expression in cancer treatment, deep learning for recurrence risk prediction, and the impact of age on oncological outcomes.

Recent Grants

Grant: Close

Proton therapy and enucleation for eye melanoma: Treatment outcomes and patient involvement in treatment decision-making and 3D-imaging treatment planning

Open Date:

Close Date:

Grant: Close

RAINBO: Refining Adjuvant treatment IN endometrial cancer Based On molecular features, the MMRd-GREEN trial

Open Date:

Close Date:

Articles (10)

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Collaborators (3)

Maxime Lafarge

University of Basel

SWITZERLAND

View details

Folkert J. van Kemenade

Erasmus University Rotterdam

NETHERLANDS

View details

Tom van Wezel

Professor

Utrecht University

NETHERLANDS

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Nanda Horeweg

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (10)

Biomarker Expression and Clinical Outcomes in International Study of Chemoradiation and Magnetic Resonance Imaging-Based Image-Guided Brachytherapy for Locally Advanced Cervical Cancer

Clinical and Molecular Characteristics of High-Risk, Recurrent, or Metastatic Endometrial Cancer That Is Human Epidermal Growth Factor Receptor 2-Low.

Prognostic value of molecular classification in stage IV endometrial cancer.

Prediction of recurrence risk in endometrial cancer with multimodal deep learning.

Prognostic impact and causality of age on oncological outcomes in women with endometrial cancer: a multimethod analysis of the randomised PORTEC-1, PORTEC-2, and PORTEC-3 trials.

Correction Method for Optical Scaling of Fundoscopy Images: Development, Validation, and First Implementation.

Molecular and Clinicopathologic Characterization of Mismatch Repair-Deficient Endometrial Carcinoma Not Related to MLH1 Promoter Hypermethylation.

<i>QPOLE</i>: A Quick, Simple, and Cheap Alternative for <i>POLE</i> Sequencing in Endometrial Cancer by Multiplex Genotyping Quantitative Polymerase Chain Reaction.

Clinical Behavior and Molecular Landscape of Stage I p53-Abnormal Low-Grade Endometrioid Endometrial Carcinomas.

Molecular Classification Predicts Response to Radiotherapy in the Randomized PORTEC-1 and PORTEC-2 Trials for Early-Stage Endometrioid Endometrial Cancer.

Collaborators (3)

Maxime Lafarge

Folkert J. van Kemenade

Tom van Wezel

Make your next move.